Meridian Medical Technologies awarded $9.9m contract to supply DuoDote

Meridian Medical Technologies, a division of Kindeva Drug Delivery, has been awarded a $9.9 million contract to supply DuoDote to the Administration for Strategic Preparedness and Response (ASPR) within the United States (U.S.) Department of Health and Human Services. 

Meridian is a health security and chemical, biological, radiological, and nuclear (CBRN) medical countermeasure provider. DuoDote is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent antidote. Meridian supplies DuoDote to U.S. and allied ministries of health and defence, as well as hospitals and civilian first responder agencies.

As part of its role in the federal response, ASPR ensures the availability and rapid deployment of lifesaving pharmaceuticals, antidotes, and other medical supplies and equipment necessary to counter the effects of biological, chemical, radiological, and nuclear threats, emerging infectious diseases, and natural disasters.

Kindeva’s commercial head - Injectables and Health Security Business Units Tom Handel, said: “Commercial partnerships are important to maintain critically necessary resources and capabilities that may be required to respond to future emergencies. Meridian has a decades long history of providing medical countermeasures to military and public health agencies and civilian responders globally. Meridian is proud to serve as a solutions provider to help the U.S. prepare and respond to emergencies, support state and local preparedness activities, and ensure availability of critical medical assets to protect the health of Americans.”